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Abstract
Background
Some observational studies have suggested that higher prenatal Vitamin D intake may be
associated with improved health outcomes in childhood. However there have been mixed
results in this area with some negative studies, especially for effects on atopic and respira-
tory outcomes. We examined the effect of prenatal Vitamin D on healthcare utilisation in the
first three years of life.
Methods
In an ethnically stratified randomised controlled trial conducted at St Mary’s Hospital Lon-
don, 180 women at 27 weeks gestation were allocated to no Vitamin D, 800 IU ergocalci-
ferol daily until delivery, or a single oral bolus of 200,000 IU cholecalciferol. Participants
were randomised in blocks of 15 using computer-generated numbers and investigators
were blinded to group assignment. Supplementation increased maternal and cord blood 25
(OH) vitamin D concentrations, but levels remained lower than current recommendations.
Primary health economic outcome was overall cost of unscheduled healthcare utilisation in
the first three years of life as documented in the child’s electronic health record. Secondary
outcomes included cost attributable to: primary and secondary healthcare visits, respiratory
and atopic complaints, cost in years 1, 2 and 3 of life and cost and frequency of prescribed
medication. All costs were calculated as pounds sterling. Differences between groups
were analysed using unpaired t-test or Mann-Whitney U test, and analysis of variance for
adjusted analyses.
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Results
We assessed 99/180 (55%) complete electronic health records, control (n = 31), daily (n =
36) and bolus (n = 32). We found no difference in total healthcare utilisation costs between
the control and daily (mean difference in costs in pounds sterling 1.02, 95%CI -1.60, 1.65;
adjusted 1.07, 95%CI -1.62, 1.86) or control and bolus groups (mean difference -1.58, 95%
CI -2.63, 1.06; adjusted –1.40, 95%CI -2.45, 1.24). There were no adverse effects of sup-
plementation reported during the trial.
Conclusions
We found no evidence that prenatal vitamin D supplementation from 27 weeks gestation to
delivery, at doses which failed to completely correct maternal vitamin D deficiency, influ-
ence overall healthcare utilisation in children in the first 3 years.
Trial Registration
Controlled-Trials.com ISRCTN68645785
Introduction
Hypovitaminosis D is an increasing problem in many regions, where sedentary, indoor life-
styles are thought to be a major contributing factor [1]. There is mixed observational evidence
with regards to the effect of pre-natal 25(OH) vitamin D status on child health outcomes. Sev-
eral studies have linked low vitamin D status to a number of resource intensive childhood
health problems including allergy and infection [2–7], in addition to the well-established effects
on bone metabolism. However, these links remain controversial with other studies reporting
no association [8–11]. Allergy alone accounts for 6% of primary care consultations and 70,000
hospital admissions a year in the UK [12] and the average pre-school UK child contracts 6–8
upper respiratory tract infections (URTIs) annually. Vitamin D supplementation during criti-
cal periods of immune development may represent a safe [13] and relatively inexpensive public
health intervention to reduce this burden. Thus far there has been a lack of randomised con-
trolled trial evidence to definitively confirm or refute the relationship between prenatal vitamin
D and childhood health outcomes found in observational studies. Data published in 2013 from
this trial, looking primarily at respiratory outcomes, found no difference between treatment
and control arms with regards to a primary outcome of wheeze [14].
In the United Kingdom, all children registered with a primary care practice have an elec-
tronic health record (e-HR). This is a contemporaneous record of all health care utilisation
from that practice. Use of primary care out of hours services (OOH) or secondary healthcare is
also recorded, and the e-HR follows the child if they move so that the e-HR forms a complete
record of a child’s healthcare utilisation from birth. Determinants of a child’s overall healthcare
utilisation are their underlying health status [15–19], parent mental health and family func-
tioning [20–22], and socioeconomic predictors (age and ethnicity of the child, family income,
area of residence, parental educational attainment and social class) [15, 19, 23–25], although
not all studies have found an effect of social class [16, 17].
We hypothesized that prenatal vitamin D supplementation during pregnancy would reduce
a child’s healthcare utilisation during the first three years of life through improved health sta-
tus, by using the e-HR to quantify our outcome total healthcare utilisation.
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Methods
Study Setting and Subjects
This was a follow up study of the offspring of 180 women who took part in an ethnically strati-
fied, parallel group, randomised controlled trial of vitamin D supplementation in pregnancy at
St Mary’s Hospital London, a university-affiliated hospital antenatal clinic, between April and
November 2007. Eligible participants were women presenting at 27 weeks gestation for routine
glucose challenge test from the following ethnic groups: Indian Asian, Middle Eastern, Afro-
Caribbean and Caucasian. Participants were excluded if there were severe congenital or devel-
opmental abnormalities likely to significantly affect respiratory health or lung function e.g. tho-
racic dystrophy. There were no withdrawal criteria for this study.
Ethics Statement
St Mary’s Hospital Research Ethics Committee approved the follow-up study (10/H0712/13).
Consent was obtained in person or over the telephone, in which case verbal consent was
taken and documented by two separate members of the research team. The ethics committee
approved verbal consenting in this manner. The confidentiality of all participants has been pre-
served under the Data Protection Act.
Study Design
Women were randomised at 27 weeks gestation to no treatment (control), 800 IU ergocalci-
ferol until delivery (daily) or a single oral dose of 200,000 IU cholecalciferol (bolus). The rando-
misation sequence was generated by an independent person using computer generated random
number lists in blocks of 15, stratified by ethnicity in a 1:1:1:1 ratio. The researcher gave partic-
ipants a study number on entry to the trial, and treatment was allocated from the hospital phar-
macy using the randomization list. Women were given instructions to swallow the tablets
whole and to avoid other multivitamin supplements containing vitamin D. This trial was con-
ducted before national guidance on routinely providing advice on vitamin D intake during
pregnancy was introduced in March 2008 [26]. No adverse effects were reported. Vitamin D
deficiency was defined as 25(OH)D<25nmol/L, and insufficiency as 25(OH)D25 but
<50nmol/L [27]. We obtained e-HR for those who consented. For analysis, two assessors
independently examined the first three e-HRs (84 consultations). The kappa score for their
assessment of total healthcare utilisation costs was 0.972, showing excellent agreement. The
remaining records were all analysed by a single assessor. All assessors were blinded to the ran-
domisation of participants, with the use of separate trial numbers, until the evaluation of all
records was complete. A complete record was defined as having data for at least 11 months out
of 12 for each year, and including all three years since birth. The flow of participants is shown
in Fig 1.
Primary and secondary outcomes
The primary outcome of the trial was 25(OH) vitamin D level at birth, and has been reported
elsewhere [28]. The primary outcome for the follow-up study was wheeze in the first 3 years of
life—this together with other clinical, physiological and immune outcomes has already been
reported [14]. The primary outcome of this health economic analysis was the total cost of
unscheduled NHS healthcare utilisation across primary and secondary care recorded in the e-
HR from birth until the child’s third birthday, including both visit costs and prescription costs.
Scheduled care such as routine developmental checks and vaccinations was not included.
Secondary outcomes were as follows: total costs for the first, second and third year of life
Prenatal Vitamin D and Childhood Healthcare Utilization: A RCT
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separately; total primary care visit costs, total secondary care visit costs, respiratory costs i.e.
healthcare utilisation attributed to wheeze, cough, upper respiratory tract infection, lower
respiratory tract infection and bronchiolitis; food allergy costs, eczema costs; prescription costs
attributable to wheezing and eczema (separately).
Primary healthcare consultations were classified according to the professional providing the
service (general practitioner, out of hours service or nurse) and location (surgery, telephone or
home visit). Entries without details were classed as ‘primary care; unknown’. Secondary health-
care utilization was classified as new outpatient appointment, follow-up outpatient appoint-
ment, accident and emergency attendance, ward admission or intensive care unit admission.
For admissions, the number of nights in hospital was recorded. Entries regarding administra-
tive tasks were not included. Coding definitions are shown in Table 1.
Visit costs
Costs were calculated according to standard NHS tariffs for 2009 in pounds sterling, that
included training and, where applicable, travel costs and direct care staff costs. All costs are
reported in pounds sterling, either as raw or natural log transformed figures. As no unit cost was
given for telephone calls with a practice nurse, this was estimated as follows: a telephone consul-
tation with an advanced nurse is six minutes long on average. When applied to the hourly rate
for client consultation with a GP practice nurse (£34) this gives an average cost of £3.40 per call.
A factor of 1.44 was applied to in hours GP utilization to give the estimated out of hours cost.
Fig 1. CONSORT flow diagram.
doi:10.1371/journal.pone.0145303.g001
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This is based on the mean cost per hour for out of hours GP services being £82.03 (Inflation
adjusted average), [29] which is 44%more than the mean cost per hour for in hours GP services
of £57.03 [30]. For secondary care new and follow-up outpatient attendances, a weighted mean
of the cost of all types of paediatric referrals for consultant led outpatient care was taken, giving
an overall mean of £198.60 for a first appointment and £155.36 for a follow-up appointment.
Similar methods were used for accident and emergency attendances, such that the weighted
mean for an A&E attendance leading to admission was £129.11, and an A&E attendance with-
out admission £94.93. This cost excludes the use of minor injury services and walk-in centres.
The details of NHS costing codes used in analysis can be found in Table 2 [31].
Prescription costs
Prescription costs were calculated from the online version of the British National Formulary
for Children 2011 [34]. These reflect the cost of drugs issued and not the cost of administration
associated with delivery to patients. The price of the pharmaceutical brand specified in the
record was taken. If no brand was specified the cheapest form of that medication with the same
mode of delivery was used. Where costs were itemized as a net price per measured unit of drug
(for example per 100ml), the price was applied proportional to the amount prescribed. Where
the drug was priced per set volume (for example per tube in the case of creams) then the num-
ber of tubes required to cover the volume prescribed was calculated. The summation of the
medication costs in each record was then subjected to deflation calculations using inflation
indices [32]. As no inflation indices for 2010/11 were available at the time of calculation, the
indices to deflate 2010 to 2009 were used twice, thereby assuming a similar rate of inflation
across that time. Deflating prices to 2008/09 brought them to the same base year as the health-
care utilization costs. The price of Anusol cream and Dentinox oral solution were not available
within the BNFC 2010 and were priced from Boots pharmacy; each of these were prescribed
once. Whether or not a child was prescribed drugs relevant to eczema (emollient creams and
bath oils, topical corticosteroids with or without antibiotics or antiseptic and calcineurin inhib-
itors), asthma (inhaled corticosteroids, B2 agonists, leukotriene inhibitors and delivery devices)
or food allergy (adrenaline autoinjectors and antihistamines) was separately recorded.
Statistical analyses
A database was assembled using Microsoft Excel. Data were explored using histograms and the
following became normally distributed after natural log transformation: total healthcare
Table 1. Diagnostic codes for electronic health records.
Outcome Deﬁnition. Any record of the following in the e-HR
Wheeze Wheeze or asthma excluding wheeze in the context of bronchiolitis
Cough Cough excluding cough in the context of URTI or LRTI
URTI URTI, pharyngitis, rhinorrhoea, laryngitis, tonsillitis, sinusitis or otitis media. Or at least two
of fever, sore throat, earache, sticky eye or cough
LRTI LRTI, chest infection, respiratory infection, bronchitis or pneumonia. Or cough with a record
of signs of infection such as crackles on auscultation
Bronchiolitis Bronchiolitis
Food
allergy
Doctor diagnosed food allergy
Eczema Eczema or eczematous skin
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).
doi:10.1371/journal.pone.0145303.t001
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Table 2. Costs used for calculation of healthcare utilization, and their source.
Type of Utilization Unit Cost
(GBP)
Source
Primary Care
Nurse In Surgery 11 Units costs by Curtis 2009 [30]
Nurse Telephone Consultation 3.4 Units costs by Curtis 2009 [30]
Nurse Home Visit 20 Units costs by Curtis 2009 [30]
GP In Surgery 35 Units costs by Curtis 2009 [30]
GP Telephone Consultation 21 Units costs by Curtis 2009 [30]
GP Home Visit 117 Units costs by Curtis 2009 [30]
OOH In Surgery 50.4 Units costs by Curtis 2009 [30] Unit
costs by Curtis 2010 [32], NAO report
OOH Care [33]
OOH Telephone Consultation 30.24 Units costs by Curtis 2009 [30] Unit
costs by Curtis 2010[32] NAO report
OOH Care[33]
OOH Home Visit 168.48 Units costs by Curtis 2009 [30]Unit costs
by Curtis 2010 [32], NAO report OOH
Care [33]
Secondary Care
First Attendance to Consultant Led OP 198.6 Appendix NSRC4 NHS Trust [31]
Follow-up Attendance to Consultant Led OP 155.36 Appendix NSRC4 NHS Trust [31]
A &E Attendance Leading to Admission 129.11 Appendix NSRC4 NHS Trust [31]
A&E Attendance Not Leading to Admission 94.93 Appendix NSRC4 NHS Trust [31]
Inpatient Stays
Kidney or Urinary Tract Infections with length of
stay less 1 day or less
392 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
LA04G [31]
Penile Conditions and Minor Procedures 18 years
and under
1307 Appendix NSRC4 NHS Trust Elective
Inpatient Code:LB32C [31]
Major Neonatal Diagnoses 2075 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Long Stay) Code:
PB01Z [31]
Major Congenital Conditions under 1 year without
CC
537 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA59D [31]
Major Congenital Conditions 1 year and over
without CC
535 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA59F [31]
Acute Febrile illness length of stay 4 days or less
without CC
378 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
WA04U [31]
Viral Infections with length of stay 2 day or more 922 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA19B [31]
Fever unspeciﬁed without CC 487 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA20B [31]
Other Viral illness without CC 368 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
WA06Y [31]
Feeding Difﬁculties and Vomiting without CC 455 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA28B [31]
(Continued)
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utilization, total visit costs, total prescription costs, total primary care costs, total year 1 costs
and overall respiratory costs. Levels of 25(OH)D at baseline in the mother, in cord blood and at
age three years in the child were all normally distributed after natural log transformation. 0.1
was added to all zero values to allow natural log transformation. The following data remained
non-normally distributed despite natural log transformation: total secondary care costs, year 2
and 3 costs, respiratory costs, food allergy costs, eczema costs and prescription costs for eczema
and wheezing medications.
Primary analysis evaluated control versus daily supplement and control versus bolus supple-
ment. Secondary analysis included bolus and daily vitamin D groups combined (combined
vitamin D) compared with the control group and the relationship between 25(OH)D levels
measured in cord blood at delivery and in the child at age three years. Differences between
groups were analysed using the independent student t-test or Mann-Whitney U test according
to whether the data were normally distributed or not. Where analysis was performed on log
transformed data, the results have undergone exponentiation for presentation in the tables.
Analysis of variance was performed on normally distributed data using potential covariates
that have been associated with healthcare utilisation in the literature including mother’s age,
mother’s age on leaving full time education, gestational age, ethnicity, parity, maternal body
mass index (BMI), smoking during pregnancy and mode of delivery [24]. Logistic regression
was used to calculate adjusted odds ratios for dichotomised data regarding prescriptions for
wheeze and eczema related drugs. All analyses were performed using SPSS version 19.0 (IBM,
Chicago USA). A value of p<0.05 was considered statistically significant.
Formal Bonferroni correction for multiple analyses was not performed, but statistical signif-
icance was interpreted cautiously where multiple analyses had been made [35].
Table 2. (Continued)
Type of Utilization Unit Cost
(GBP)
Source
Infectious and Non-Infectious Gastroenteritis
without CC
459 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA21B [31]
Intermediate Mouth or Throat Procedures 18
years and under with CC
1799 Appendix NSRC4 NHS Trust Elective
Inpatient Code: CZ02S [31]
Other Respiratory Diagnoses without CC 342 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
DZ19C [31]
Acute Bronchiolitis without CC 489 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA15B [31]
Acute Bronchiolitis with CC 573 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA15A [31]
Lower Respiratory Tract Disorders without Acute
Bronchiolitis with length of stay 1 day or more
without CC
544 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
PA14D [31]
Minor Skin disorders category 2 without CC 396 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
JD05C [31]
Non-Malignant General Abdominal Disorders with
length of stay 0 days
410 Appendix NSRC4 NHS Trust Non-
Elective Inpatient (Short Stay) Code:
FZ47C [31]
GP- general practitioner, OOH—out of hours, OP- outpatient, CC- critical care.
doi:10.1371/journal.pone.0145303.t002
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Results
Of the 180 offspring from the original trial, we successfully obtained 130 e-HRs from their
GP’s between January and May 2011. 31 had incomplete data and could not be used, leaving
99/180 (55%) infants with complete e-HR data for analysis. An additional 12 records were
incomplete but had at least one year’s health data for analysis. Incomplete records were due to
inadequate GP summaries or where the patient had moved GP practice over the last three
years and we were unable to obtain the old or new records. Only records with complete data
were used for primary analysis. Participant flow through the study can be found in Fig 1.
Table 3 shows the characteristics of children for whom complete e-HR data was obtained and
analysed and those who were not analysed (either incomplete or not received). There were
minor differences between groups with a slightly higher proportion of Middle Eastern children
with incomplete records and a slightly higher proportion of Black children for whom no record
was received. However, the groups remain relatively similar in most respects. The characteris-
tics of children with complete records in each randomization group are shown in Table 4.
Effect of prenatal vitamin D supplementation on healthcare utilisation
There was no significant difference in the primary outcome measure, total unscheduled health-
care utilisation, between treatment groups (Fig 2). Mean difference between control and daily
vitamin D supplementation in Ln transformed total costs was—0.02 (95%CI -0.47, 0.50);
adjusted mean difference 0.07 (95%CI -0.48, 0.62). For bolus vitamin D supplementation ver-
sus controls the mean difference was -0.46 (95%CI-0.97, 0.06); adjusted mean difference -0.34
(95%CI -0.90, 0.22).
We also found no significant difference in secondary outcomes including total prescription
costs, total visit costs, costs in years 1, 2 and 3 and costs specific to respiratory or allergic disor-
ders, between offspring in the daily treatment group compared to controls (Table 5). There
was weak evidence that secondary care health utilisation costs (p = 0.048) and year 3 costs
(p = 0.045) were reduced in the bolus group (Table 6). When treatment groups were combined
for analysis, no difference was found from controls (Table 7).
Effect of prenatal vitamin D supplementation on need for prescription
medications
Prescribing data were also dichotomized according to whether any prescription was made in
the first three years of life. There was weak evidence that offspring of mothers who received
bolus vitamin D were more likely to have been prescribed a wheezing medication (p = 0.05),
and that offspring of mothers who received daily vitamin D were more likely to have been pre-
scribed an eczema medication (p = 0.04) (Table 8). We therefore evaluated the number of pre-
scriptions for medicated skin creams or wheezing medications, to further explore the possible
association with eczema and wheezing medications. Here we found no difference in the num-
ber of prescriptions issued for medicated skin creams (median 1.0 IQR 0.0, 2.0 combined vita-
min D versus 0.0 (0.0, 2.0) controls; p = 0.27) or wheezing medications (median 0.0 IQR 0.0,
1.0 combined vitamin D versus 0.0 (0.0, 0.0) controls; p = 0.42). There were insufficient data to
analyse bolus and daily vitamin D groups separately for this outcome.
Association between prenatal or postnatal vitamin D level and
healthcare utilisation
Of the 99 offspring with complete e-HR data, cord levels of 25(OH)D were available for 79,
and 25(OH)D levels at age three years for 65. There was no correlation between either of these
Prenatal Vitamin D and Childhood Healthcare Utilization: A RCT
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measures and any healthcare utilisation outcome (Fig 3A and 3B; Table 9; Table 10). To further
investigate the weak evidence for a link between cord blood 25(OH) vitamin D concentration
and eczema cost (Table 9), we analysed whether there was a relationship between cord 25(OH)
vitamin D level and prescription of a medicated cream (aOR 2.52, p = 0.10, 95% CI 0.85–7.47)
Table 3. Characteristics of children with complete e-HR data, incomplete e-HR data and for whom no e-HR data were received.
Complete(n = 99) Incomplete(n = 12) Not Received(n = 69)
Male sex, n (%) 52/99 (53) 7/12 (58) 34/69 (49)
Gestational age, weeks 39.6 (1.57) 40.5 (1.27) 39.6 (1.27)
Delivery by caesarean section, n (%) 30/99 (30) 4/12 (33) 23/69 (33)
Cord blood 25(OH) Vitamin D available, n (%) 79/99 (80) 7/12 (58) 55/69 (80)
Mean cord blood 25(OH) Vit D (nmol/L) 26.9 (13.6) 30.6 (19.1) 24.3 (11.0)
Maternal Ethnicity, n (%)
Asian 25/99 (25) 3/12 (25) 17/69 (25)
Middle Eastern 25/99 (25) 5/12 (42) 15/69 (22)
Black 21/99 (21) 2/12 (17) 21/69 (30)
Caucasian 28/99 (28) 2/12 (17) 16/69 (23)
Maternal age at booking, years 32 (6.45) 30 (5.47) 30 (6.02)
Maternal smoking in pregnancy, n (%) 13/99 (13) 0/12 (0) 6/69 (9)
Multiparous, n (%) 65/99 (66) 5/12 (42) 31/69 (45)
Maternal BMI at booking 27 (6.07) 26 (5.51) 25 (4.99)
Maternal 25(OH) Vit D at delivery available n(%) 86/99 (87) 10/12 (83) 62/69 (90)
Maternal 25(OH) Vit D at delivery 42.65 (22.2) 44.0 (22.3) 37.9 (18.0)
Continuous data are presented as mean (standard deviation). BMI = body mass index.
doi:10.1371/journal.pone.0145303.t003
Table 4. Characteristics of children with complete e-HR data.
Control (n = 31) Daily (n = 36) Bolus (n = 32)
Male sex, n (%) 15/31 (48) 22/36 (61) 17/32 (53)
Gestational age, months 39.92 (1.28) 39.40 (1.53) 39.72 (1.66)
Delivery by caesarean section, n (%) 10/31 (32) 10/36 (28) 10/32 (31)
Cord blood 25(OH) Vitamin D available, n (%) 24/31 (77) 29/36 (81) 26/32 (81)
Mean cord blood 25(OH) Vit D (nmol/L) 18.8 (9.4) 34.1 (16.3) 26.4(8.31)
Maternal Ethnicity, n (%)
Asian 6/31 (19) 10/36 (28) 9/32 (28)
Middle Eastern 11/31 (35) 8/36 (22) 6/32 (19)
Black 5/31 (16) 8/36 (22) 8/32 (25)
Caucasian 9/31 (29) 10/36 (28) 9/32 (28)
Maternal age at booking, years 30 (7) 32 (6) 32 (6)
Maternal highest education, years 20 (3) 20 (4) 20 (3)
Family history of atopy, n (%) 13/29 (45) 23/35 (63) 15/31 (48)
Maternal smoking in pregnancy, n (%) 5/31 (16) 5/36 (14) 3/31 (10)
Number children in household 2 (1) 2 (1) 3 (1)
Multiparous, n (%) 19/31 (61) 25/36 (69) 21/32 (66)
Maternal BMI > 30 at booking, n (%) 9/31 (29) 4/36 (11) 4/32 (12.5)
Maternal 25(OH) Vit D at delivery available n(%) 26/31(83) 33/36 (92) 27/32 (84)
Maternal 25(OH) Vit D at delivery 33.0 (17.6) 55.3(27.0) 36.5(9.5)
Continuous and ordinal data are presented as mean (standard deviation). BMI = body mass index.
doi:10.1371/journal.pone.0145303.t004
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and whether cord 25(OH) vitamin D was associated with the number of eczema medications
prescribed (r = 0.07, p = 0.91, 95% CI -0.72–7.80). No evidence for an association was found.
Discussion
We evaluated whether two specific dosing regimens of prenatal vitamin D supplementation
could reduce health care utilisation in the first three years of life. We found no consistent evi-
dence for a treatment effect on overall or disease-specific unscheduled healthcare utilisation in
the first three years, although it should be noted that neither of the intervention regimens
resulted in adequate vitamin D levels in mothers or cord blood, judged by current international
vitamin D recommendations [36, 37]. We found no evidence that prenatal vitamin D status is
related to healthcare utilisation, however one might argue that the very small number of sub-
jects with adequate vitamin D status limited the power of this analysis. These data contrast
with recent findings that higher dose vitamin D during pregnancy and infancy can reduce
upper respiratory tract infections in infancy [38]. Our new findings suggest that prenatal
maternal vitamin D levels may be less important than postnatal infant vitamin D levels for
determining infant health outcomes, at least within the insufficient/deficient range. Strength is
lent to this conclusion when the healthcare utilisation data are contextualised within the other
clinical data obtained from this trial in which supplementation did not influence odds of respi-
ratory or allergic symptoms, or measures of lung function/inflammation and immune develop-
ment [14]. Our data failed to show any significant difference between the total healthcare costs
of children from control vs. supplemented mothers, with an adjusted mean difference of £1.17
(p = 0.52). Considering the cost of the pharmaceuticals required for intervention (as per 2011);
of £50.18 for daily supplement and £10.59 for bolus dosing, this suggests that supplementation
solely for this purpose would not be cost-effective. [39]
Studies in other populations, usually with higher prenatal vitamin D status than ours, have
found an inverse relationship between cord blood 25(OH) vitamin D level and child health
outcomes [4]. However intervention trials have not yet shown this relationship to be a causal
one. The findings from our trial, the first prenatal vitamin D intervention trial to report child
Fig 2. Effect of prenatal vitamin D randomisation on total healthcare utilisation in the first three years
of life. Horizontal bars represent medians and p values are for adjusted analyses.
doi:10.1371/journal.pone.0145303.g002
Prenatal Vitamin D and Childhood Healthcare Utilization: A RCT
PLOSONE | DOI:10.1371/journal.pone.0145303 December 23, 2015 10 / 19
health outcomes, suggest that either the dosing regimen used in this study was inadequate, or
that the relationship between cord blood 25(OH) vitamin D and child health seen in observa-
tional studies may be related to hidden confounders. It is important to consider the generalisa-
bility and limitations of these conclusions. First the effect (or lack of effect) of the specific
timing and dose of vitamin D used in our study cannot be generalised to other dosing and tim-
ing schedules. While our interventions did result in at least 50% higher cord blood 25(OH)D
concentrations compared with no treatment, cord blood levels were significantly lower in our
intervention groups [daily dose 26nmol/l (IQR 17–45); bolus dose 25nmol/l (IQR 18–34)] than
in studies that have found protective associations between higher early life 25(OH)D levels on
wheezing or respiratory tract infections in early childhood (Camargo 44nmol/L (IQR 29–78)
[4]; Morales 74nmol/L (IQR 56–93) [6]; Belderbos 82nmol/L (SE 3.5) [40]). The recent New
Zealand intervention trial showing reduced acute respiratory tract infections between 6 and 18
months of life in offspring of Vitamin D supplemented mothers found a higher vitamin D dose
was necessary for clinical efficacy, and infants were supplemented in addition to mothers [38].
Maternal serum 25(OH) vitamin D levels in that trial were higher at randomization, and rose
to a higher level in the supplemented groups—from ~60 to ~100 nmol/L; compared to ~26 to
~40 nmol/L in our trial. At the time of the initial trial the national UK recommendation for
Table 5. Healthcare utilisation in the first three years of life. Daily vitamin D versus control.
n Control* n Daily* Mean difference
(95% CI)
p n Adjusted** mean difference
(95% CI)
p
Total cost† 31 1176.14 (437.03,
3165.29)
36 1187.97 (441.42,
3197.10)
1.02 (-1.60, 1.65) 0.95 53 1.07 (-1.62, 1.86) 0.81
All Visits† 31 1130.03 (419.90,
3041.18)
36 1118.79 (407.48,
3071.74)
-1.01 (-1.65, 1.60) 0.95 53 1.02 (-1.70, 1.79) 0.93
Prescription cost† 31 25.28 (4.06, 157.60) 36 35.52 (11.59,
108.85)
1.40 (-1.49, 2.94) 0.36 53 1.65 (-1.43, 3.90) 0.25
Year 1 cost† 31 287.15 (38.09,
2164.62)
36 383.75 (86.49,
1702.75)
1.34 (-1.75, 3.16) 0.50 53 1.67 (-1.58, 4.39) 0.30
Year 2 cost 31 247 (103, 607) 36 248 (123, 487) - 0.92 - - -
Year 3 cost 31 239 (103, 552) 36 212 (96, 463) - 0.57 - - -
Primary care
cost†
31 387.61 (145.47,
1032.77)
36 450.39 (242.26,
837.15)
1.15 (-1.28, 1.72) 0.47 53 1.34 (-1.16, 2.05) 0.20
Secondary care
cost
31 632 (206, 1853) 36 368 (155, 1502) - 0.42 - - -
Wheeze cost 31 0 (0, 0) 36 0 (0, 0) - 0.71 - - -
Cough cost 31 0 (0, 36) 36 0 (0, 36) - 0.26 - - -
URTI cost 31 180 (36, 324) 36 150 (54, 234) - 0.78 - - -
LRTI cost 31 0 (0, 0) 36 0 (0, 0) - 0.75 - - -
Bronchiolitis cost 31 0 (0, 0) 36 0 (0, 0) - 0.89 - - -
Overall resp cost† 31 170.72 (27.39,
1064.22)
36 141.17 (27.11,
735.10)
-1.21 (-3.16, 2.14) 0.69 - - -
Food allergy cost 31 0 (0, 0) 36 0 (0, 0) - 0.35 - - -
Eczema cost 31 0 (0, 88) 36 0 (0, 36) - 0.62 - - -
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).
All costs are in pounds sterling.
*Mean ± 95% CI or Median (IQR)
**Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle
Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors.
†Analysis performed on Ln data, results have undergone exponentiation for presentation in tables.
doi:10.1371/journal.pone.0145303.t005
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supplementation during pregnancy was 400IU (10mcg) once daily. This continues to be rec-
ommended and is integrated into the ‘Healthy Start’multivitamin tablets. However, guidance
from the National Institute for Clinical Excellence and Royal College of Obstetricians and
Gynaecologists in the UK now acknowledge this as a minimum dose for all pregnant or breast-
feeding women and that higher dosing should be considered in those at high risk of vitamin D
deficiency [41, 42]. More recent guidance from the Institute of Medicine estimates 400IU as
average daily requirement in adults in the US and Canada but recommends that supplementa-
tion of 600IU would ensure most people achieved sufficiency in their target population [37, 43]
In a review by Holick et al. in 2011 greater intervention was suggested with baseline dosing of
600IU, increasing to 1500-2000IU in those at risk of deficiency. In addition, higher thresholds
of 25(OH) Vitamin D were recommended for deficiency (<50nmol/l) and insufficiency (52.5–
72.5nmol/l) [36]. Despite our daily dosing being above the baseline recommendation and
showing increase in maternal and cord blood 25(OH) Vitamin D, by these definitions only
around 30% of the women in the trial achieved sufficiency, therefore our data likely reflect out-
comes looking at the shift from deficient to insufficient and not full replenishment. With the
endorsement of not only different dosing regimes but different safe upper limits (4,000 IU/day
Table 6. Healthcare utilization in the first three years of life. Bolus vitamin D versus control.
n Control* n Bolus* Mean difference
(95% CI)
p n Adjusted** mean difference
(95% CI)
p
Total cost† 31 1176.14 (437.03,
3165.29)
31 742.48 (257.24,
2413.08)
-1.58 (-2.63, 1.06) 0.08 49 -1.40 (-2.45, 1.24) 0.23
All visit costs† 31 1130.03 (419.90,
3041.18)
32 706.27 (239.85,
2079.74)
1.60 (-2.69, 1.05) 0.08 49 -1.43 (-2.53, 1.23) 0.21
All prescription
cost†
31 25.28 (4.06, 157.60) 32 22.42 (4.85, 103.54) 1.12 (-2.61, 2.08) 0.79 49 1.23 (-1.95, 3.00) 0.63
Year 1 cost† 31 287.15 (38.09,
2164.62)
32 223.63 (62.80,
796.32)
1.28 (-2.97, 1.82) 0.56 49 1.02 (-2.36, 2.46) 0.96
Year 2 cost 31 247 (103, 607) 32 202 (101, 603) - 0.75 - - -
Year 3 cost 31 239 (103, 552) 32 142 (36, 333) - 0.04 - - -
Primary care cost† 31 387.61 (145.47,
1032.77)
32 383.75 (169.02,
871.32)
1.02 (-1.60, 1.55) 0.95 49 1.01 (-1.57, 1.60) 0.98
Secondary care
cost
31 632 (206, 1853) 32 313 (0, 848) - 0.04 - - -
Wheeze visit cost 31 0 (0, 0) 32 0 (0, 0) - 0.22 - - -
Cough visit cost 31 0 (0, 36) 32 0 (0, 36) - 0.59 - - -
URTI visit cost 31 180 (36, 324) 32 108 (72, 255) - 0.91 - - -
LRTI visit cost 31 0 (0, 0) 32 0 (0, 36) - 0.31 - - -
Bronchiolitis visit
cost
31 0 (0, 0) 32 0 (0, 0) - 0.59 - - -
Overall resp cost† 31 170.72 (27.39,
1064.22)
32 137.00 (15.96,
1176.15)
-1.25 (-3.42, 2.20) 0.66 - - -
Food allergy cost 31 0 (0, 0) 32 0 (0, 0) - 1.00 - - -
Eczema cost 31 0 (0, 88) 32 0 (0, 36) - 0.77 - - -
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).
All costs are in pounds sterling.
*Mean ± 95% CI or Median (IQR)
**Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle
Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors.
†Analysis performed on Ln data, results have undergone exponentiation for presentation in the table.
doi:10.1371/journal.pone.0145303.t006
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Table 7. Healthcare utilization costs in the first three years of life. Combined vitamin D versus control.
n Control* n Combined* Mean
difference
p n Adjusted** mean
difference
p
Total cost† 31 1176.14 (437.03,
3165.29)
68 953.37 (333.62,
2724.39)
-1.23 (-1.92,
1.27)
0.36 84 -1.17 (-1.90, 1.39) 0.52
All visit cost† 31 1130.03 (419.90,
3041.18)
68 897.85 (311.06,
2591.52)
-1.27 (-1.95,
1.25)
0.31 84 -1.21 (-1.97, 1.35) 0.45
All prescription cost† 31 25.28 (4.06, 157.60) 68 28.50 (7.32, 111.05) 1.14 (-1.70,
2.18)
0.70 84 1.34 (-1.49, 2.66) 0.41
Year 1 total cost† 31 287.15 (38.09,
2164.62)
68 298.87 (74.44,
1199.91)
1.04 (-1.93,
2.08)
0.91 84 1.25 (-1.70, 2.63) 0.56
Year 2 total cost 31 247 (103, 607) 68 244 (108, 558) - 0.81 - - -
Year 3 total cost 31 239 (103, 552) 68 168 (60, 430) - 0.14 - - -
Primary care visit cost† 31 387.61 (145.47,
1032.77)
68 415.72 (202.35,
854.06)
1.07 (-1.32,
1.52)
0.70 84 1.16 (-1.25, 1.67) 0.42
Secondary care visit
cost
31 632 (206, 1853) 68 316 (103, 1050) - 0.11 - - -
Wheeze visit cost 31 0 (0,0) 68 0 (0, 0) - 0.37 - - -
Cough visit cost 31 0 (0, 36) 68 0 (0, 36) - 0.33 - - -
URTI visit cost 31 180 (36, 324) 68 130 (72, 252) - 0.82 - - -
LRTI visit cost 31 0 (0, 0) 68 0 (0, 24) - 0.68 - - -
Bronchiolitis visit cost 31 0 (0, 0) 68 0 (0, 0) - 0.70 - - -
Overall resp cost† 31 170.72 (27.39,
1064.22)
68 138.38 (347.23,
1107.65)
-1.23 (2.92,
1.93)
0.64 - - -
Food allergy cost 31 0 (0, 0) 68 0 (0, 0) - 0.50 - - -
Eczema cost 31 0 (0, 88) 68 0 (0, 36) - 0.90 - - -
URTI (Upper respiratory tract infection), LRTI (Lower respiratory tract infection).
All costs are in pounds sterling.
*Mean ± 95% CI or Median (IQR)
**Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle
Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors
†Analysis performed on Ln data, results have undergone exponentiation for presentation in table.
doi:10.1371/journal.pone.0145303.t007
Table 8. Any prescription for wheezing or eczema. Daily, bolus and combined groups vs controls.
Control n (%) Treatment group, n (%) Unadjusted OR (95%CI) p n aOR1 (95% CI) p
Wheezing medications
Daily vs controls 4/31 (12.9) 8/36 (22.2) 1.93 (0.66, 1.97) 0.32 66 3.19 (0.57, 17.77) 0.19
Bolus vs controls 4/31 (12.9) 11/32 (34.4) 3.54 (0.98, 12.70) 0.05 62 4.07 (0.98, 16.84) 0.05
Combined vs controls 4/31 (12.9) 19/68 (27.9) 2.62 (0.81, 8.49) 0.11 96 3.08 (0.85, 11.24) 0.09
Eczema medications
Daily vs controls 14/31 (45.2) 22/36 (61.1) 1.91 (0.72, 5.06) 0.19 66 3.60 (1.05, 12.34) 0.04
Bolus vs controls 14/31 (45.2) 15/32 (46.9) 1.07 (0.40, 2.89) 0.89 62 2.13 (0.60, 7.53) 0.24
Combined vs controls 14/31 (45.2) 37/68 (54.4) 1.45 (0.62, 3.40) 0.39 96 2.22 (0.82, 6.02) 0.12
aOR (Adjusted odds ratio).
1Adjusted for mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian, Asian, Middle
Eastern, Black), parity, BMI>30, smoking during pregnancy and mode of delivery (vaginal, instrumental or caesarean) as potential cofactors.
doi:10.1371/journal.pone.0145303.t008
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(IOM) versus upto 10,000IU/day (Holick et al.), there remains an important question whether
prenatal vitamin D supplementation at doses which reliably achieve sufficiency in the target
population, can improve healthcare outcomes for young children. The relationship between
prenatal vitamin D status and child health outcomes may not be linear. Given that some obser-
vational studies suggest adverse child respiratory health outcomes are associated with very
high maternal vitamin D level during pregnancy, empiric data are needed before high dose pre-
natal vitamin D supplementation can be routinely recommended [44].
Fig 3. Cord and childhood 25(OH)D levels and total healthcare utilisation in the first three years of life.Adjusted correlation (Beta coefficient, β)
between 25(OH) vitamin D levels measured at A) Birth and total healthcare utilization at age three years B) Age three years and total health care
utilization by age three years.
doi:10.1371/journal.pone.0145303.g003
Table 9. Cord 25(OH)D levels and healthcare utilisation in the first three years of life.
Outcome n p β or ρ n Adjusted1 β p
Ln total healthcare 79 0.58 -0.06 76 -0.02 0.89
Ln all visit cost 79 0.54 -0.07 76 -0.01 0.93
Ln all prescription cost 79 0.78 -0.03 76 0.12 0.36
Ln year 1 cost 79 0.57 -0.07 76 0.01 0.94
Year 2 cost 79 0.76 -0.04 - - -
Year 3 cost 79 0.57 0.07 - - -
Ln primary care cost 79 0.96 -0.01 76 0.12 0.36
Secondary care cost 79 0.62 -0.06 - - -
Wheeze cost 79 0.95 0.01 - - -
Cough cost 79 0.98 -0.003 - - -
UTRI cost 79 0.42 -0.09 - - -
LRTI cost 79 0.28 0.12 - - -
Bronchiolitis cost 79 0.55 -0.07 - - -
Ln Overall Resp cost 79 0.35 -0.10 76 -0.05 0.74
Food allergy cost 79 0.86 -0.02 - - -
Eczema cost 79 0.12 0.18 - - -
β (Beta coefﬁcient), ρ (Spearmans correlation coefﬁcient), URTI (Upper respiratory tract infection, LRTI (Lower respiratory tract infection).
1Adjusted for treatment group, mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian,
Asian, Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors.
doi:10.1371/journal.pone.0145303.t009
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A limitation of our findings is that healthcare utilization may be too crude, with large health
effects required to influence total healthcare utilisation. However, the national framework for
health provision in the UK provides a powerful resource of objective information, the merit of
which has been validated in a systematic review [45, 46]. When prevalence is based on a combi-
nation of diagnosis and prescribing patterns, as we have done, the reliability of this resource
further increases [47]. A further limitation of the study is its small size and wide confidence
intervals, so that a small effect of prenatal vitamin D on child healthcare utilization in the first
3 years cannot be confidently excluded. However the data were negative when evaluated in dif-
ferent ways, in both adjusted and unadjusted analyses. Overall the data suggest that a clinically
meaningful relationship between this regime of vitamin D supplementation in pregnancy in a
deficient population, or these levels of vitamin D in cord-blood or at three years of age, and
healthcare utilization is unlikely.
Other limitations of this study include the risk of selection bias with follow up rate of only
55% of those randomised. Analyses with imputation for missing data were not undertaken due
to the relatively small sample size. However, the characteristics of those included in analysis
were similar to those that were excluded. Adjusted analyses were consistent with unadjusted
analyses suggesting a low probability that confounding factors have altered the findings of this
trial. This was a diverse ethnic group. Variation in healthcare use has been reported between
ethnic minorities in the UK, with lower levels of asthma diagnosis and treatment in people
from the Indian subcontinent [48, 49] but higher consultation frequency [50, 51]. However,
multivariate analysis of our data showed that although maternal ethnicity correlated with 25
(OH) vitamin D level there was no relationship between maternal ethnicity and our measures
of healthcare utilization in this trial.
In conclusion we have found no evidence that supplementation of a vitamin D deficient,
urban mixed race population with either a single oral bolus dose of 200,000 IU cholecalciferol
Table 10. Childhood 25(OH)D levels and healthcare utilisation in the first three years of life.
Outcome n p β or ρ n Adjusted1 β p
Ln total healthcare 65 0.52 -0.08 63 -0.07 0.68
Ln all visit cost 65 0.49 -0.09 63 -0.08 0.66
Ln all prescription cost 65 0.88 0.02 63 -0.007 0.97
Ln year 1 cost 65 0.63 -0.06 63 -0.05 0.76
Year 2 cost 65 0.52 -0.08 - - -
Year 3 cost 65 0.24 -0.15 - - -
Ln primary care cost 65 0.86 0.02 63 0.12 0.93
Secondary care cost 65 0.70 -0.05 - - -
Wheeze cost 65 0.72 0.05 - - -
Cough cost 65 0.56 0.07 - - -
UTRI cost 65 0.21 -0.16 - - -
LRTI cost 65 0.50 -0.09 - - -
Bronchiolitis cost 65 0.94 -0.01 - - -
Ln overall Resp cost 65 0.11 -0.20 63 -0.14 0.45
Food allergy cost 65 - - - - -
Eczema cost 65 0.86 0.02 - - -
β (Beta coefﬁcient), ρ (Spearmans correlation coefﬁcient), URTI (Upper respiratory tract infection, LRTI (Lower respiratory tract infection).
1Adjusted for treatment group, mother’s age, mother’s age on leaving education and gestational age as potential covariates, and ethnicity (Caucasian,
Asian, Middle Eastern, Black), parity, BMI>30, smoking during pregnancy, mode of delivery (vaginal, instrumental or caesarean) as potential cofactors.
doi:10.1371/journal.pone.0145303.t010
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at 27 weeks or 800 IU ergocalciferol daily from 27 weeks until delivery had any effect on child
healthcare utilization in the first 3 years of life. Moreover we found no evidence of a relation-
ship between cord blood 25(OH) vitamin D level and healthcare utilization in this population.
Although our confidence in the findings is limited by the small sample size, these data suggest
that if prenatal vitamin D is used to promote improved child health outcome, then a postnatal
component to treatment, and/or or higher doses may be needed.
A recent systematic review of prenatal vitamin D supplementation found heterogeneous
study designs and inconsistent findings [52]. Outcomes of a subsequent intervention trial sug-
gest that higher dose vitamin D, and possibly combined mother/infant supplementation may
be needed for positive health effects on the child [38]. In that context further data are awaited
from two larger randomised controlled trials, VDARRT [53] and ABCVitaminD [54], to estab-
lish whether higher dose daily prenatal vitamin D supplementation will impact on child health
outcomes.
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